Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNuformix Regulatory News (NFX)

Share Price Information for Nuformix (NFX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.175
Bid: 0.17
Ask: 0.18
Change: -0.01 (-5.41%)
Spread: 0.01 (5.882%)
Open: 0.185
High: 0.00
Low: 0.00
Prev. Close: 0.185
NFX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Half-year Report

13 Oct 2017 07:00

RNS Number : 5001T
Levrett PLC
13 October 2017
 

 

Levrett Plc

("Levrett" or the "Company")

 

Interim Results

for the period ended 30 September 2017

 

Levrett, a company formed to acquire a target company with realisable or developed commercial technologies in the pharmaceutical and biotechnology sector, announces its interim results for the period ended 30 September 2017.

For further information please contact:

Levrett plc

John Lidgey - Chairman

 

+44 (0)20 7183 4342

 

Whitman Howard Limited

Financial Advisor to Levrett

Nick Lovering

 

+44 (0)20 7659 1234

 

Gable Communications Ltd

John Bick

 

+44 (0)20 7193 7463

 

levrett@gablecommunications.com

 

 

CHAIRMAN'S STATEMENT

FOR THE PERIOD ENDED 30 September 2017

 

Introduction

 

These are the results for Levrett Plc for the interim period ended 30 September 2017.

 

The company was incorporated on 10 June 2015 and was admitted to the Official List of the UK Listing Authority on 17 December 2015.

 

Financial review

 

In the six months to 30 September 2017, the Company recorded a loss for the period of £77,504 (a loss per share of 0.08 pence). This includes certain fees in relation to the identification of Nuformix Limited as a possible acquisition target, due diligence and advisory fees related to the transaction.

 

F J Lidgey

 

Chairman

 

13 October 2017

LEVRETT PLC

 

INTERIM STATEMENT OF COMPREHENSIVE INCOME

FOR THE PERIOD ENDED 30 September 2017

 

 

 

Unaudited

Unaudited

Audited

period ended

period ended

year ended

30 September 2017

30 September 2016

31 March

 2017

£

£

£

Revenue

-

-

-

 

 

Administrative expenses

 

 

(77,504)

 

 

(510,957)

 

 

(685,057)

 

LOSS BEFORE TAX

 

 

 

(77,504)

 

(510,957)

 

(685,057)

Tax

-

-

-

LOSS FOR THE PERIOD

(77,504)

(510,957)

(685,057)

Other comprehensive income/(expense)

-

-

-

TOTAL COMPREHENSIVE EXPENSE

FOR THE PERIOD

 

(77,504)

 

(510,957)

 

(685,057)

 

Loss before tax and total comprehensive expense for the period are all attributable to the equity shareholders of the company.

Loss per share

Basic and diluted (pence)

(0.08) p

(0.53) p

(0.72) p

 

 

 

 

 

 

 

 

 

 

 

 

LEVRETT PLC

 

INTERIM STATEMENT OF FINANCIAL POSITION

FOR THE PERIOD ENDED 30 September 2017

 

 

Unaudited

Unaudited

Audited

30 September

30 September

31 March

2017

2016

2017

Notes

£

£

£

ASSETS

Current assets

 

Trade and other receivables

142,556

35,310

13,727

Cash and cash equivalents

 

699

 

111,358

 

5,895

 

143,255

146,668

19,622

TOTAL ASSETS

143,255

146,668

19,622

EQUITY AND LIABILITIES

Equity

Share capital

3

95,750

95,750

95,750

Share premium account

737,440

734,315

737,440

Share Option Reserve

22,695

22,695

22,695

Retained earnings

(1,112,981)

(861,376)

(1,035,477)

Total equity attributable to equity holders of the parent

(257,096)

(8,616)

(179,592)

Current liabilities

Trade and other payables

400,351

155,284

199,214

TOTAL LIABILITIES

400,351

155,284

199,214

TOTAL EQUITY AND LIABILITIES

143,255

146,668

19,622

 

LEVRETT PLC

 

INTERIM STATEMENT OF CHANGES IN EQUITY

FOR THE PERIOD ENDED 30 September 2017

 

 

Share

Share

Premium

Share Option

Retained

capital

account

Reserve

earnings

Total

£

£

£

£

£

On Incorporation

-

-

-

-

-

Total comprehensive expense to date

 

-

 

-

 

-

 

(861,376)

 

(861,376)

Shares issued

95,750

 734,315

22,695

-

852,760

Unaudited at 30 September 2016

95,750

734,315

22,695

(861,376)

(8,616)

Total comprehensive expense to 31 March 2017

 

-

 

-

 

-

 

(174,101)

 

(174,101)

Grant of share options

-

3,125

-

-

3,125

 

 

 

 

 

 

 

 

 

 

 

 

Audited at 31 March 2017

95,750

737,440

22,695

(1,035,477)

(179,592)

Total comprehensive expense for period

 

-

 

-

 

-

 

(77,504)

 

(77,504)

Shares issued

-

-

-

-

-

Unaudited at 30 September 2017

95,750

737,440

22,695

(1,112,981)

(257,096)

 

All equity is attributable to equity shareholders of the company.

 

Share premium

 

Represents amounts subscribed for share capital in excess of its nominal value, net of directly attributable issue costs.

 

LEVRETT PLC

 

INTERIM STATEMENT OF CASH FLOWS

FOR THE PERIOD ENDED 30 September 2017

 

 

 

Unaudited

Unaudited

Audited

period ended

period ended

Year ended

30 September 2017

30 September 2016

31 March 2017

 

£

£

£

Operating activities

Loss before tax

(77,504)

(510,957)

(685,057)

 

Changes in working capital:

Share Issue, option of warrants

-

-

3,125

(Increase)/ Decrease in trade and other receivables

(128,829)

7,268

28,851

Increase in trade and other payables

201,137

112,834

156,763

Net cash used in operating activities

(5,196)

(390,855)

(496,318)

Financing activities

Share issue

-

-

-

Net cash generated from financing activities

(5,196)

(390,855)

(496,318)

Taxation

-

-

-

Net decrease in cash and cash equivalents

(5,196)

(390,855)

(496,318)

Cash and cash equivalents at the start of the period

5,895

502,213

502,213

Cash and cash equivalents at the end of the period

699

111,358

5,895

LEVRETT PLC

 

NOTES TO THE INTERIM FINANCIAL INFORMATION

FOR THE PERIOD ENDED 30 September 2017

 

 

1 General information

 

Levrett Plc is a publicly listed company incorporated and domiciled in England. The address of its registered office is Suite 31, 2nd Floor, 107 Cheapside, London. EC2V 6DN.

 

The Company is listed on the Official List.

This interim financial information was approved for issue on 13 October 2017.

 

2 Accounting policies

 

2.1 Basis of preparation

The interim financial information comprises the Statements of Financial Position at 30 September 2017, the Statements of Comprehensive Income, Changes in Equity and Cash Flows for the period ended 30 September 2017 and the related notes of Levrett Plc, (hereinafter referred to as "the interim financial information").

 

The interim financial information has been prepared in accordance with IAS 34, 'Interim Financial Reporting' as adopted by the European Union. In preparing this information, management have used the accounting policies set by the Company. The auditors' report on the full statutory accounts for the year ended 31 March 2017 included an Emphasis of Matter paragraph with regards to going concern. The accounts for the year ended 31 March 2017 have been filed with the Registrar of Companies.

 

This interim financial information does not constitute a set of statutory accounts under the requirements of the Companies Act 2006 and is neither audited nor reviewed.

 

This document (the Interim Statement 2017) will be published on the company's website and will be publicly available from the London Stock Exchange regulatory publications. The maintenance and integrity of the Levrett Plc website is the responsibility of the directors. Legislation in the UK governing the preparation and dissemination of accounts may differ from legislation in other jurisdictions.

 

2.2 Going concern

These financial statements have been prepared on the going concern basis based on the current cash flow projections for the following twelve months. In particular, the directors have assumed that the acquisition of Nuformix Limited and the placing of ordinary shares will be approved by the Company's shareholders on 13 October 2017.

 

LEVRETT PLC

 

NOTES TO THE INTERIM FINANCIAL INFORMATION

FOR THE PERIOD ENDED 30 September 2017

 

 

3

Share capital

Unaudited

Unaudited

Audited

 

period ended

period ended

year ended

 

30 September

2017

30 September

2016

31 March

2017

 

£

£

£

 

Issued and fully paid

 

95,750,000 Ordinary shares issued of £0.001 each

95,750

95,750

 

95,750

95,750

95,750

95,750

 

On Admission to the Official List, 45,750,000 of the above issued share capital was placed at a price of £0.02 per share with the premium (net of the issue costs) being shown in the share premium account.

 

4

Dividends paid and proposed

Equity dividends on ordinary shares:

 

No interim dividend was paid or is proposed for the period ended 30 September 2017.

 

5

Loss per share

 

The calculations of loss per share are based on the following results and number of shares:

 

Unaudited

Unaudited

Audited

 

period ended

period ended

year ended

 

30 September 2017

30 September 2016

31 March

 2017

 

£

£

£

 

 

Loss for the financial period

(77,504)

(510,957)

(685,057)

 

 

Weighted average number of shares for diluted loss per share

95,750,000

 

 

95,750,000

95,750,000

 

 

 

At 30 September 2017, the number of ordinary shares in issue was 95,750,000.

 

 

 

 

 

 

 

 

 

LEVRETT PLC

 

DIRECTORS AND OFFICERS

 

 

Directors

P D Hughes

F J Lidgey

A H Reeves

Secretary

St James Corporate Services Limited

Company Number

09632100

Registered office

Suite 31

2nd Floor, 107 Cheapside

London

EC2V 6DN

www.levrett.com

Broker & Corporate Broker

Whitman Howard Limited

1st Floor, Connaught House

1-3 Mount Street

London

W1K 3NB

 

 

Auditors

 

 

haysmacintyre

26 Red Lion Square

London

WC1R 4AG

Solicitors

Shakespeare Martineau LLP

One America Square

Crosswall

London

EC3N 2SG

Registrars

Capita Registrars Limited

The Registry

34 Beckenham Road

Beckenham

Kent

BR3 4TU

 

 

 

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IR MMMMGMZGGNZZ
Date   Source Headline
19th Mar 20242:39 pmRNSResult of AGM
1st Mar 20247:00 amRNSSubscription to raise £150,000
15th Jan 202411:30 amRNSPosting of Annual Report and Notice of AGM
3rd Jan 20247:00 amRNSResults for the period ended 30 September 2023
18th Dec 20237:00 amRNSNXP001 Update
23rd Oct 20237:00 amRNSNotice of Allowance of NXP002 Patent in Japan
18th Sep 20237:00 amRNSNXP001 Update
24th Aug 20231:22 pmRNSResult of Annual General Meeting
31st Jul 20232:00 pmRNSNotice of AGM
26th Jul 20232:55 pmRNSHolding(s) in Company
2nd Jun 20237:00 amRNSInvestor Online Q&A
25th May 20237:00 amRNSChange of Auditor
22nd May 20237:00 amRNSUnaudited Interim Report
18th May 20237:00 amRNSNXP002 Inflammation and Duration of Action Update
26th Apr 202310:55 amRNSHolding(s) in Company
17th Apr 20237:00 amRNSSubscription to raise £70,000 & issue of Warrants
27th Mar 20237:00 amRNSNXP002 Update
13th Mar 20237:00 amRNSChange of Accounting Reference Date
15th Feb 20237:00 amRNSNXP002 Update
3rd Jan 20231:37 pmRNSHolding(s) in Company
20th Dec 20221:02 pmEQSNuformix hoping to 'initiate discussions with major pharma' in 2023
20th Dec 20227:00 amRNSNXP004 Update
13th Dec 20227:00 amRNSHalf-year Report
5th Dec 20227:00 amRNSResignation of Auditor
16th Nov 20228:50 amRNSHolding(s) in Company
4th Nov 20227:00 amRNSInvestor Webinar
23rd Sep 20227:00 amRNSNXP002 Update
23rd Sep 20227:00 amRNSNXP002 Update
25th Aug 20222:39 pmRNSResult of AGM
19th Aug 20228:57 amRNSHolding(s) in Company
10th Aug 20227:00 amRNSNXP002 Completion of Tolerability Studies
1st Aug 202212:13 pmRNSPosting of Annual Report and Notice of AGM
28th Jul 20227:01 amRNSBoard Changes
28th Jul 20227:00 amRNSAnnual Results for the year ended 31 March 2022
5th Jul 20227:00 amRNSNXP002 data to be presented at 2022 ERS Congress
29th Jun 20227:00 amRNSNXP004 Update
27th Jun 20227:00 amRNSNXP002 Update
20th Jun 20227:00 amRNSHolding(s) in Company
31st May 20227:00 amRNSDirectorate Change
30th May 20227:00 amRNSCorporate Update
12th Apr 20227:00 amRNSSecond tranche of Lanstead subscription shares
11th Apr 20223:54 pmRNSHolding(s) in Company
8th Apr 202211:21 amRNSHolding(s) in Company
7th Apr 20223:44 pmRNSHolding(s) in Company
5th Apr 20226:07 pmRNSHolding(s) in Company
28th Mar 20227:00 amRNSNXP004 Patent
2nd Mar 20227:00 amRNSAppointment of Dr Dan Gooding as Consultant
1st Mar 20227:00 amRNSChange of Auditor
14th Feb 20224:37 pmRNSHolding(s) in Company
8th Feb 20227:00 amRNSOxilio NXP-001 formulation development contract

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.